Scarica l'app Stockscreener
91.00
1.61%
1.44
Pre-mercato:
92.15
1.15
+1.26%
Precedente Chiudi:
$89.56
Aprire:
$89.56
Volume 24 ore:
818.32K
Relative Volume:
1.05
Capitalizzazione di mercato:
$6.07B
Reddito:
$189.76M
Utile/perdita netta:
$-196.54M
Rapporto P/E:
-29.27
EPS:
-3.1087
Flusso di cassa netto:
$-156.63M
1 W Prestazione:
-8.22%
1M Prestazione:
-15.72%
6M Prestazione:
-12.98%
1 anno Prestazione:
+70.99%
Intervallo 1D:
$88.03
$91.66
Intervallo di 1 settimana:
$87.19
$103.25
Portata 52W:
$45.91
$122.20
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
Nome
Rhythm Pharmaceuticals Inc
Settore
Industria
Telefono
857-264-4280
Indirizzo
222 BERKELEY STREET, BOSTON, MA
Compare RYTM vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
91.00 | 5.98B | 189.76M | -196.54M | -156.63M | -3.1087 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-19 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-11-25 | Iniziato | Citigroup | Buy |
| 2025-11-05 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-07-10 | Iniziato | Goldman | Buy |
| 2025-07-07 | Iniziato | Leerink Partners | Outperform |
| 2025-04-07 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-03-05 | Ripresa | Stifel | Buy |
| 2025-01-02 | Iniziato | Jefferies | Buy |
| 2024-12-20 | Iniziato | Oppenheimer | Outperform |
| 2024-10-21 | Iniziato | Guggenheim | Buy |
| 2024-09-18 | Iniziato | H.C. Wainwright | Buy |
| 2024-09-17 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-05-08 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-12-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-08-01 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-01-18 | Ripresa | Canaccord Genuity | Buy |
| 2022-08-08 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-08-05 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-06-17 | Reiterato | Needham | Buy |
| 2022-03-02 | Ripresa | Stifel | Buy |
| 2022-02-17 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2021-12-08 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-14 | Ripresa | Goldman | Neutral |
| 2021-08-04 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-08-04 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-30 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-01-08 | Iniziato | Goldman | Sell |
| 2019-07-12 | Aggiornamento | Stifel | Hold → Buy |
| 2019-07-08 | Iniziato | Canaccord Genuity | Buy |
| 2019-03-13 | Iniziato | Ladenburg Thalmann | Buy |
| 2018-09-07 | Ripresa | Morgan Stanley | Overweight |
| 2018-06-25 | Reiterato | Needham | Buy |
| 2018-06-15 | Reiterato | Needham | Buy |
| 2017-10-30 | Iniziato | BofA/Merrill | Buy |
| 2017-10-30 | Iniziato | Needham | Buy |
Mostra tutto
Rhythm Pharmaceuticals Inc Borsa (RYTM) Ultime notizie
Rhythm Pharmaceuticals (RYTM) Is Down 8.2% After Positive TRANSCEND Data And FDA sNDA Progress - simplywall.st
Proposed sale of 64,540 common shares under registered plan (RYTM) - Stock Titan
HC Wainwright Issues Negative Estimate for RYTM Earnings - MarketBeat
Rhythm Pharmaceuticals (RYTM) CAO exercises RSUs, withholds shares for taxes - Stock Titan
Jefferies reiterates Rhythm Pharmaceuticals stock rating on trial outlook By Investing.com - Investing.com Canada
RYTM (NASDAQ: RYTM) brokered notice for 35,460-share sale on 03/03/2026 - Stock Titan
Does Rhythm Pharmaceuticals (RYTM) Share Price Reflect Its Obesity Treatment Potential Today - simplywall.st
Rhythm Pharmaceuticals price target lowered to $110 from $125 at H.C. Wainwright - Yahoo Finance
Rhythm Pharmaceuticals (RYTM) CFO exercises options, acquiring 6,099 shares - Stock Titan
Canaccord Genuity Lowers Price Target for RYTM, Maintains Buy Ra - GuruFocus
Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Lowered to $140.00 at Canaccord Genuity Group - MarketBeat
HC Wainwright Cuts Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target to $110.00 - MarketBeat
RYTM: HC Wainwright & Co. Lowers Price Target Despite Maintainin - GuruFocus
Why Is Rhythm Pharmaceuticals Stock Trading Higher Today?Rhythm Pharmaceuticals (NASDAQ:RYTM) - Benzinga
Rhythm Pharmaceuticals, Inc. (RYTM) Investor Outlook: Robust Analyst Ratings Signal Potential 51.69% Upside - DirectorsTalk Interviews
Canaccord lowers Rhythm Pharmaceuticals stock price target to $140 - Investing.com
Rhythm Says New Late-Stage Data for Obesity Drug Shows Strong Weight Loss, Hunger Reduction - marketscreener.com
Rhythm Highlights Positive Phase 3 Data in Hypothalamic Obesity - TipRanks
Rhythm Pharmaceuticals posts 18.8% placebo‑adjusted BMI reduction in TRANSCEND Phase 3 52‑week data - TradingView
Rhythm Pharmaceuticals (Nasdaq: RYTM) adds positive Phase 3 HO data ahead FDA PDUFA - Stock Titan
Rhythm Pharmaceuticals Nears Key FDA Calls With Global Growth Potential - Sahm
Rhythm Pharmaceuticals (RYTM) Reveals Promising Phase 3 Trial Da - GuruFocus
A Look At Rhythm Pharmaceuticals (RYTM) Valuation After Recent Pullback In Share Price - Yahoo Finance
Rhythm Pharmaceuticals says PDUFA goal date for setmelanotide is March 20, 2026 - marketscreener.com
Rhythm Pharmaceuticals Says PDUFA Goal Date For Setmelanotide Is March 20, 2026 - TradingView
Obesity drug shows 18.8% BMI edge, backing first FDA bid in acquired HO - Stock Titan
Artisan Partners Limited Partnership Buys 62,362 Shares of Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
RYTM SEC FilingsRhythm Pharmaceu 10-K, 10-Q, 8-K Forms - Stock Titan
Rhythm Pharmaceuticals, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:RYTM) 2026-02-27 - Seeking Alpha
Wells Fargo & Company Cuts Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target to $136.00 - MarketBeat
Rhythm Pharmaceuticals (RYTM) Price Target Lowered by Wells Farg - GuruFocus
RBC Capital Adjusts Price Target on Rhythm Pharmaceuticals to $140 From $145, Maintains Outperform Rating - marketscreener.com
Citizens Jmp Raises Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target to $176.00 - MarketBeat
Is Rhythm Pharmaceuticals Inc. stock risky to hold now2025 Major Catalysts & Free Fast Entry Momentum Trade Alerts - mfd.ru
Needham & Company LLC Issues Pessimistic Forecast for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price - MarketBeat
Guggenheim Issues Positive Forecast for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price - MarketBeat
RYTM Stock Update: Guggenheim Maintains 'Buy', Raises Price Targ - GuruFocus
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q4 2025 Earnings Call Transcript - Insider Monkey
Guggenheim raises Rhythm Pharmaceuticals stock price target on guidance By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Citizens raises Rhythm Pharmaceuticals stock price target on HO approval outlook - Investing.com Nigeria
Rhythm Pharmaceuticals (RYTM) Financials 2026Income Statement and Balance Sheet - MarketBeat
Decoding Rhythm Pharmaceuticals Inc (RYTM): A Strategic SWOT Ins - GuruFocus
Rhythm Pharmaceuticals (NASDAQ:RYTM) Issues Quarterly Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat
Rhythm Pharmaceuticals files for mixed shelf - marketscreener.com
Rhythm Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Rhythm Pharmaceuticals Inc. (referred to as Rhythm Pharmaceuticals) recently disclosed that some of its shareholders plan to further sell up to 2.4 million shares of common stock. - Bitget
Rhythm Pharmaceuticals Files For Mixed Shelf - TradingView
Rhythm Pharmaceuticals Inc (RYTM) Q4 2025 Earnings Call Highligh - GuruFocus
Stifel reiterates Buy on Rhythm Pharmaceuticals stock, $131 target - Investing.com Nigeria
Stifel reiterates Buy on Rhythm Pharmaceuticals stock, $131 target By Investing.com - Investing.com India
Rhythm Pharmaceuticals Inc Azioni (RYTM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.11%
6.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):